Mumbai: On August 25, 2025, Rajiv Anand officially took charge as the Managing Director and CEO of IndusInd Bank, backed by the board and pending shareholders’ approval. His appointment spans three ...

Rajiv Anand who took early retirement from Axis Bank this week, has now been appointed as MD & CEO of IndusInd Bank, with effect from August 25. Anand's appointment is for three years. His appointment ...

One of the most significant recent developments at IndusInd Bank is the appointment of Rajiv Anand as the new Managing Director and CEO, marking a critical turning point for the bank. According to ...

Veteran banker Rajiv Anand has taken charge as IndusInd Bank's chief executive and managing director Veteran banker Rajiv Anand has taken charge as IndusInd Bank‘s chief executive and managing ...

India's IndusInd Bank expects to grow in line with the country's banking sector next year, following efforts to clean up its books and complete an ...

In Rajiv Anand’s first interaction with a few business head of IndusInd Bank, his message was loud and clear – compliance first, anything else can come later. The meeting, which is said to have ...

MUMBAI: Shares of private lender IndusInd Bank on Tuesday rose 5.6 percent intraday to hit a high of ₹848.80 on the BSE following the announcement of Rajiv Anand’s appointment as the bank’s new ...

IndusInd Bank promoter Ashok Hinduja on Tuesday said the lender's newly appointed chief executive and managing director, Rajiv Anand, will help realise the full potential of the bank. The promoter ...

Sunil Mehta, Chairman of IndusInd Bank, is set to step down in January following his term conclusion amid an ongoing organisational overhaul.

Veteran banker and former Axis Bank Deputy MD Rajiv Anand today assumed charge as MD, CEO of IndusInd Bank for a period of three years, according to an exchange filing. businessline was the first to ...

IndusInd Bank Chairman Sunil Mehta will exit in January as the lender advances its management overhaul after governance failures, heavy losses, and investor pressure for stronger oversight.

Since the start of the pandemic, the pharmaceutical industry's reliance on overseas manufacturing has been in the spotlight. But domestic production, or onshoring, isn't as easy or foolproof a ...